Geode Capital Management LLC Sells 42,127 Shares of Qiagen (NYSE:QGEN)

Geode Capital Management LLC lessened its position in Qiagen (NYSE:QGEN) by 3.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,055,671 shares of the company’s stock after selling 42,127 shares during the period. Geode Capital Management LLC owned 0.46% of Qiagen worth $48,107,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. GAMMA Investing LLC grew its stake in shares of Qiagen by 806.5% in the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock worth $26,000 after acquiring an additional 500 shares during the last quarter. Toronto Dominion Bank purchased a new stake in shares of Qiagen during the 2nd quarter valued at about $27,000. Massmutual Trust Co. FSB ADV increased its holdings in Qiagen by 39.8% during the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after buying an additional 243 shares during the last quarter. Headlands Technologies LLC raised its holdings in Qiagen by 396.6% in the 2nd quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock worth $113,000 after purchasing an additional 2,189 shares during the period. Finally, CWM LLC raised its stake in shares of Qiagen by 11.5% in the third quarter. CWM LLC now owns 2,792 shares of the company’s stock worth $127,000 after buying an additional 287 shares during the period. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Analysts Set New Price Targets

QGEN has been the topic of several research analyst reports. Jefferies Financial Group restated a “buy” rating and issued a $54.00 price objective (up from $42.00) on shares of Qiagen in a research report on Tuesday, December 10th. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research note on Thursday, October 17th. Finally, HSBC downgraded Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a research report on Thursday, October 17th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $51.88.

Qiagen Stock Up 0.3 %

Shares of NYSE QGEN opened at $44.82 on Tuesday. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39. The firm has a 50-day moving average price of $43.33 and a 200 day moving average price of $43.76. Qiagen has a 52 week low of $39.03 and a 52 week high of $47.44. The stock has a market capitalization of $10.23 billion, a price-to-earnings ratio of 114.92, a price-to-earnings-growth ratio of 3.52 and a beta of 0.35.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.